Hypertension: By combining the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and ...

Noting that the proposed protocol is insufficient to prove the clinical relevance of the lower strength of ...

Every day, doctors prescribe medication for patients with high blood pressure that includes an angiotensin II receptor ...

FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...